• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine Research >Teneligliptin As an Initial Therapy for Newly Diagnosed, Drug Naive Subjects With Type 2 Diabetes
【24h】

Teneligliptin As an Initial Therapy for Newly Diagnosed, Drug Naive Subjects With Type 2 Diabetes

机译：Teneligliptin作为新诊断为2型糖尿病的初治药物的初始治疗

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Teneligliptin is a novel, highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor. The aim of this study is to explore the glycemic and non-glycemic efficacies of teneligliptin as an initial therapy. Methods: Newly diagnosed, drug naive Japanese subjects with type 2 diabetes (T2DM) were assigned to 20 mg/day teneligliptin monotherapy (n = 31). At 3 months, levels of glycemic and other parameters were compared with those at baseline. Results: Significant reductions of HbA1c (from 10.34 ± 2.06 to 8.38 ± 2.23%) and fasting blood glucose (FGB, from 211.3 ± 68.4 to 167.3 ± 70.2 mg/dL) levels were observed without any clinically significant adverse events. However, significant increases of uric acids (UA) levels were observed and two subjects reported mild hypoglycemic events. Homeostasis model assessment-B (HOMA-B) levels significantly increased, while high HOMA-R levels significantly decreased. Significant correlations were observed between the changes (Δ) of HbA1c and those of HOMA-B, and between ΔFBG and ΔHOMA-R. No changes in lipid and body weight were noted. Conclusions: Teneligliptin might be effectively and safely used as an initial therapy for newly diagnosed T2DM. Glycemic efficacy of teneligliptin is obtained through activating beta-cell function as well as decreasing insulin resistance.J Clin Med Res. 2014;6(4):287-294doi: http://dx.doi.org/10.14740/jocmr1841e
机译：背景：替利格列汀是一种新型的高选择性二肽基肽酶-4（DPP-4）抑制剂。这项研究的目的是探索替尼格列汀作为初始疗法的血糖和非血糖功效。方法：将刚诊断为初次使用药物的日本2型糖尿病（T2DM）受试者分配为20 mg /天的替尼格列汀单药治疗（n = 31）。在3个月时，将血糖和其他参数水平与基线水平进行比较。结果：观察到HbA1c水平显着降低（从10.34±2.06降低到8.38±2.23％）和空腹血糖（FGB，从211.3±68.4降低到167.3±70.2 mg / dL），没有任何临床上明显的不良事件。然而，观察到尿酸（UA）水平显着增加，两名受试者报告了轻度降血糖事件。稳态模型评估B（HOMA-B）水平显着增加，而高HOMA-R水平显着降低。观察到HbA1c和HOMA-B的变化（Δ）之间以及ΔFBG和ΔHOMA-R之间的显着相关性。没有发现脂质和体重的变化。结论：特立格列汀可能被有效，安全地用作新诊断的T2DM的初始疗法。通过激活β细胞功能以及降低胰岛素抵抗性来获得替奈格列汀的降血糖功效.J Clin Med Res。 2014; 6（4）：287-294doi：http://dx.doi.org/10.14740/jocmr1841e

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号